Clinical Trial Update: A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) [Phase 2]

View source ↗

Summary

Completed Phase 2 trial evaluating tolerability and immunogenicity of the V504 HPV vaccine candidate when administered with GARDASIL for HPV-related diseases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Genital Warts
• Human Papillomavirus Infection
• Vaginal Cancer
• Vulvar Cancer

Drugs mentioned

• Gardasil (human papillomavirus vaccine)
• V504 (HPV vaccine candidate)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cervical Cancer, Vulvar Cancer | Phase 2 | Status: COMPLETED